Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-328-9 | CAS number: 81-14-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 990
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 4'-tert-butyl-2',6'-dimethyl-3',5'-dinitroacetophenone
- EC Number:
- 201-328-9
- EC Name:
- 4'-tert-butyl-2',6'-dimethyl-3',5'-dinitroacetophenone
- Cas Number:
- 81-14-1
- Molecular formula:
- C14H18N2O5
- IUPAC Name:
- 1-(4-tert-butyl-2,6-dimethyl-3,5-dinitrophenyl)ethanone
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source of test material: Givaudan Corporation (Clifton, N J, USA).
- Purity: 98%
Test animals
- Species:
- rat
- Strain:
- other: Sprague-Dawley Crl:CDR(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Canada Inc., St Constant, Quebec, Canada)
- Age at study initiation: 41 - 44 days old
- Weight at study initiation: males 141-182 g and females 113-148 g
- Housing: Housed individually in stainless-steel cages
- Diet (e.g. ad libitum): Standard laboratory rodent chow (Certified Purina" Rodent Chow No. 5002)
- Water: Tap water ad libitum
- Acclimation period: At least 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature : 21 ± 3°C
- Humidity: 50± 20%
- Photoperiod : 12-hr light/dark cycle
Administration / exposure
- Type of coverage:
- open
- Vehicle:
- other: Phenylethyl alcohol
- Details on exposure:
- TEST SITE
- Area of exposure: Clipped unabraded surface of the backs of the rats daily
- % coverage: Approximately 25% of the body surface area
TEST MATERIAL
- Concentration (if solution): 3.75, 12.0, 37.5, 120.0 mg/mL for 7.5, 24, 75 or 240 mg/kg bw/day
- Constant volume or concentration used: Yes (Appropriate amounts of the test materials were dissolved in the vehicle to yield a constant dose volume of 2 ml/kg body weight across all groups). Dosing solutions were freshly made each week and adjusted each week to achieve the desired dose on a mg/kg bw/day basis.
VEHICLE
Phenylethyl alcohol (PEA), which was supplied by PPF International, Inc. (East Hanover, N J, USA).
USE OF RESTRAINERS FOR PREVENTING INGESTION: Yes (Elizabethan-type collars to prevent ingestion of the test substances) - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of the dose solutions were periodically checked for accuracy of formulation throughout the study but no specific data provided.
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- 7 days per week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 7.5 mg/kg bw/day (nominal)
- Dose / conc.:
- 24 mg/kg bw/day (nominal)
- Dose / conc.:
- 75 mg/kg bw/day (nominal)
- Dose / conc.:
- 240 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- Musk Ketone: 15 males and 15 females
PEA: 30 males and 30 females - Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: The rats were observed twice a day for mortality and morbidity.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: The rats were observed once a day for clinical signs. Once a week they were given a detailed physical examination.
DERMAL IRRITATION (if dermal study): Yes
- Time schedule for examinations: The rats were observed once a day for dermal irritation.
BODY WEIGHT: Yes
- Time schedule for examinations: The rats were weighed once a day.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
HAEMATOLOGY: Yes
Blood samples were obtained from all rats that survived to the end of the study (except those selected for neuropathological evaluations) by venepuncture of the orbital sinus under light anaesthesia or from the abdominal aorta following an ip injection of sodium pentobarbital. Haematological were performed on blood from ten rats/sex in the vehicle control group, and in the groups given 24 or 240 mg musk ketone. The rats were starved overnight before blood sampling. The haematological parameters examined included haematocrit, haemoglobin, methaemoglobin, red blood cell (RBC) count, RBC morphology, platelet count, white blood cell count (total and differential) and Wintrobe's constants (calculated).
CLINICAL CHEMISTRY: Yes
Blood samples were obtained from all rats that survived to the end of the study (except those selected for neuropathological evaluations) by venepuncture of the orbital sinus under light anaesthesia or from the abdominal aorta following an ip injection of sodium pentobarbital. Clinical chemical evaluations were performed on blood from ten rats/sex in the vehicle control group, and in the groups given 24 or 240 mg musk ketone. The rats were starved overnight before blood sampling. The clinical chemical parameters examined were alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, calcium, chloride, cholesterol, creatinine, creatinine phosphokinase, glucose, y-glutamyl transferase, inorganic phosphate, lactic dehydrogenase, magnesium, total bilirubin, total protein, triglycerides and uric acid.
NEUROBEHAVIOURAL EXAMINATION: Yes
At the end of the treatment period, three rats/sex/dose (musk ketone) and seven rats/sex (control group) were randomly selected for neuropathological examination. Where possible, this selection was limited to those rats that showed clinical signs of neurotoxicity. Selected rats were deeply anaesthetized with sodium barbitone or pentobarbital and systemically perfused with fixatives according to standard procedures. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Except for those selected for neuropathological evaluation, all surviving rats were killed by an ip injection of sodium pentobarbital or by ether anaesthesia followed by exsanguination from the abdominal aorta. All of these rats, and any that died or were killed in extremis during the study, were examined at necropsy for gross pathological changes.
The following organs were weighed and retained at necropsy: adrenals, brain, epididymis (fixed in Zenker's fluid), heart, kidneys, liver, ovaries, pituitary, testes (fixed in Zenker's fluid), and thyroid and parathyroids. In addition, the
following tissues and organs were retained: abdominal aorta, bone marrow (femur), caecum, colon, duodenum, oesophagus, eyes, head, ileum, jejunum, lungs, mesenteric lymph nodes, mammary gland, pancreas, prostate, salivary gland, sciatic nerve, seminal vesicles, skeletal muscle, skin, spinal cord, spleen, stomach, thymus, trachea, urinary bladder, uterus, vagina, all gross lesions and all tissue masses. All organs and tissues were fixed and preserved in neutral buffered 10% formalin, unless otherwise indicated.
HISTOPATHOLOGY: Yes
Histopathological examination was performed on the following selected organs and tissues from rats in the vehicle control groups and the groups given the 240 mg/kg bw/day musk ketone: heart, kidneys, liver, ovaries, skin, testes, thyroid and any tissues with gross abnormalities. - Statistics:
- Differences in body weights, relative organ weights, and haematological and clinical chemical values were analysed by appropriate tests including chi-square test (with Yate's correction), Fisher's exact probability test, Bartlett's test ANOVA, and Kruskal-Wallis and Dunn's test.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The signs and symptoms associated with the demise of the rats in all groups were generally non-specific. They included reduced muscle tone, abnormal respiration and, occasionally, ataxia.
- Dermal irritation:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Apart from variable desquamation, and occasional atony of the skin, there were no significant dermatological changes at the treatment site that could be attributed to the test substances.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One female in the vehicle control group, one male given 24 mg/kg bw/day musk ketone and one male given 240 mg/kg bw/day musk ketone died or were killed before the end of dosing (Table 2).
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Throughout the study, the body weights of males and females given the high dose of musk ketone and of the females given 75 mg/kg/day were significantly lower than those of the vehicle controls (Figs 2 and 3), whereas food consumption was similar to or greater than that of the controls. No effects of musk ketone on body weight or food consumption were observed at other doses.
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Throughout the study, the body weights of males and females given the high dose of musk ketone and of the females given 75 mg/kg/day were significantly lower than those of the vehicle controls (Figs 2 and 3), whereas food consumption was similar to or greater than that of the controls. No effects of musk ketone on body weight or food consumption were observed at other doses.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The males and females in the high-dose musk ketone groups showed variations in haematological parameters, notably decreases in haemoglobin, haematocrit, RBC counts and mean corpuscular volume (data not shown). However, all of the values fell within historical ranges for this strain of rat and were not considered to be of any biological significance. There was no correlation with the observed deaths.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- There were no effects on clinical chemistry parameters (data not shown).
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Neither during nor at the end of the study were specific treatment-related functional impairments observed that were attributable to musk ketone (data not shown).
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The livers of females exposed to the high dose of musk ketone were increased in weight, compared with vehicle controls, but this was not associated with any pathological findings (Table 3).
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no gross changes in any of the organs examined, including the testes, which could be attributed to treatment (data not shown)..
- Neuropathological findings:
- no effects observed
- Description (incidence and severity):
- There was no evidence of neurotoxicity in any of the rats exposed to musk ketone although detailed neuropathological examination of specially prepared sections of the central and peripheral nervous systems was carried out (data not shown).
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In musk ketone groups, microscopic lesions were variable and generally non-specific; there was no correlation with the observed deaths (data not shown)
- Histopathological findings: neoplastic:
- not examined
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 75 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 75 mg/kg bw/day (nominal)
- System:
- hepatobiliary
- Organ:
- liver
- Treatment related:
- yes
- Dose response relationship:
- no
Applicant's summary and conclusion
- Conclusions:
- In a dermal repeated dose toxicity study in Sprague-Dawley Crl:CDR(SD) rat, the NOAEL for males and females was 75 mg/kg bw/day, based on the relative liver weight changes in females.
- Executive summary:
In a repeat-dose dermal toxicity study (Ford and Api, 1990), musk ketone (98%) was applied to the clipped unabraded skin of 15 Sprague-Dawley Crl:CDR(SD) rats/sex/dose at dose levels of 0, 24, 75, 240 mg/kg bw/day, 7 days/week during a 90-day period.
One female in the vehicle control group, one male given 24 mg/kg bw/day musk ketone and one male given 240 mg/kg bw/day musk ketone died or were killed before the end of dosing. Apart from variable desquamation, and occasional atony of the skin, there were no significant dermatological changes at the treatment site that could be attributed to the test substance. Throughout the study, the body weights of males and females given the high dose of musk ketone and of the females given 75 mg/kg/day were significantly lower than those of the vehicle controls, whereas food consumption was similar to or greater than that of the controls. No effects of musk ketone on body weight or food consumption were observed at other doses.
The males and females in the high-dose musk ketone groups showed variations in haematological parameters, notably decreases in haemoglobin, haematocrit, RBC counts and mean corpuscular volume. However, all of the values fell within historical ranges for this strain of rat and were not considered to be of any biological significance. There was no correlation with the observed deaths. There were no effects on clinical chemistry parameters.
The livers of females exposed to the high dose of musk ketone were increased in weight, compared with vehicle controls, but this was not associated with any pathological findings. There were no gross changes in any of the organs examined, including the testes, which could be attributed to treatment. In musk ketone groups, microscopic lesions were variable and generally non-specific; there was no correlation with the observed deaths.
Neither during nor at the end of the study were specific treatment-related functional impairments observed that were attributable to musk ketone. There was no evidence of neurotoxicity in any of the rats exposed to musk ketone although detailed neuropathological examination of specially prepared sections of the central and peripheral nervous systems was carried out.
The NOAEL for musk ketone in males and females was 75 mg/kg bw/day, based on the relative liver weight changes in females.
This dermal toxicity study in the rat is acceptable and satisfies the guideline requirement for a repeat-dose dermal toxicity study (OECD 411).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.